THCX News and Press, Spinnaker ETF Series The Cannabis From 11/30/21

GAGE growing with retail and cultivation assets in MI. TerrAscend deal poised to close in early ’22. Reduce rating to hold and price target to $1.91 reflecting TerrAscend deal. Potential for upside in short term on TerrAscend stock gains on legislative news or additiona...

Exchange traded funds can play a valuable role for many cannabis investors. Three years after legalization in Canada, there is now enough data to evaluate cannabis ETF performance. The AdvisorShares Pure Cannabis ETF has been a superior performer in both good and bad markets. ...

Kristen Yoder, host of The CannaBS Detector and a veteran of the industry, gives an unvarnished take on the cannabis industry. Kristen's #1 complaint about the industry. Why she'd rather be short cannabis stocks than long and where she does feel comfortable putting her money. ...

The cannabis ETF universe has expanded to the point that a variety of interesting choices are available. Cannabis ETFs can play a valuable role for investors, offering a list of advantages. CNBS has a number of characteristics that in combination may lead to superior ETF performan...

Timely, edifying episode with industry expert Brady Cobb. Recent cannabis legislation; moving from optics to real reform. SAFE Banking, uplisting and what it all means for cannabis investors. MSOs, ETFs new and old, future valuations, Florida and NY/NJ markets. Selling to Cres...

Q3 results in line with estimates. 22 Target Revenue remains $800M, adjusted EBITDA guidance reduced on low end, now at $250M to $300M (was $300M). Expanding presence in IL with Dispensary 33 acquisition. Confident that additional M&A looms given management interest and ca...

Q3/21 miss on pricing pressure. Expect lower flower pricing to continue into 2022. Pricing pressure furthers our positive view on LOWLF’s differentiated initiatives put in place by management including brand acquisition, buildout of processing business and decision not to a...

Q3/21 EBITDA miss on delayed product approval in PA, MA cultivation underperformance and inflated freight costs. Expect freight costs to linger into ’22. Management reduced ’21 adjusted EBITDA guidance by nearly 20% at midpoint while stating that revenues would come ...

Q3/21 results were just the second as a vertically integrated operator. Continue to forecast strong growth and margin expansion as operations scale and acquired assets are integrated. Believe could be a takeout candidate as MSOs continue to target Colorado and other mature US cann...

An executive panel discussion that makes sense of cannabis investing today, including the recent Republican led bill, JPMorgan trading restrictions and SAFE banking. All star panel includes Blake Schroeder, CEO of Medical Marijuana, Luis Merchan, CEO of Flora Growth and Becky Postar, ...